Inmune Bio ( (INMB) ) has released its Q3 earnings. Here is a breakdown of the information Inmune Bio presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inmune Bio Inc. is a clinical-stage biotechnology company focused on developing therapies to treat diseases caused by inflammation and immune system dysfunction, with a focus on Alzheimer’s, cancer, and chronic inflammation. The company operates primarily in the biotechnology sector and employs a precision medicine approach in its research and development efforts.
In its latest earnings report for the quarter ended September 30, 2025, Inmune Bio Inc. reported a net loss of $6.47 million, a significant improvement from the $12.09 million loss in the same quarter of the previous year. The company also highlighted a cash position of $27.73 million, up from $20.92 million at the end of 2024, reflecting successful fundraising activities.
Key financial metrics from the report show that the company had no revenue for the quarter, consistent with its status as a clinical-stage company. Operating expenses decreased significantly to $7.43 million from $12.29 million in the same period last year, largely due to reduced research and development costs. However, the company recorded an impairment charge of $16.51 million earlier in the year related to its Alzheimer’s drug candidate, XPro, which failed to meet primary endpoints in a Phase 2 trial.
Despite the challenges, Inmune Bio has been actively managing its financial resources, as evidenced by its successful capital raises through direct offerings, which have bolstered its cash reserves. The company continues to explore strategic partnerships to advance its pipeline, particularly for its Alzheimer’s and cancer therapies.
Looking ahead, Inmune Bio’s management remains focused on securing additional funding and partnerships to sustain its operations and advance its clinical programs. The company’s ability to navigate these financial and operational challenges will be crucial in determining its future success in the competitive biotechnology landscape.